Novavax lays off hundreds of employees as new CEO goes into rescue mode
Novavax is laying off approximately 400 workers as part of a sweeping campaign by first-year CEO John Jacobs to adapt the vaccine developer to a post-pandemic reality.
The reorg will amount to around 20% to 25% of Novavax’s workforce, according to the company, depending on how existing headcount is tallied. The changes follow a round of cost cuts in April, which lowered first-quarter expenses by $50 million but did not involve letting employees go, according to the company.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.